FDA
-
-
-
-
-
-
-
New Data Added to TRINTELLIX® (vortioxetine) Labeling Demonstrated Superiority Over Escitalopram in Improving SSRI-Induced Sexual Dysfunction in Patients with Major Depressive Disorder
-
-
-
-
-
-
-
New Phase 3 Data Show Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Ulcerativ
-
-
-
-
-
-
-
Takeda’s Zika Vaccine Candidate Receives U.S. FDA Fast Track Designation
-
-
-
-
-
-
-
Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma
-
-
-
-
-
-
-
Takeda to Feature ALUNBRIG™ (brigatinib) Data from Pivotal Phase 2 ALTA Trial at 18th World Conference on Lung Cancer
-
-
-
-
-
-
-
Takeda Announces Publication of ALUNBRIG™ (brigatinib) Pivotal Phase 2 ALTA Clinical Trial Data in Journal of Clinical Oncology
-
-
-
-
-
-
-
Takeda to Acquire ARIAD Pharma (ARIA) for $5.2B
-
324,034 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

